Misako Nagasaka

University of California Irvine School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (11)

PURPOSE The mammalian target of rapamycin (mTOR) inhibitor everolimus is US Food and Drug Administration-approved for advanced pancreatic neuroendocrine neoplasms (pNENs), yet resistance is common, necessitating the identification of resistance mechanisms for effective treatment strategies. Previous studies suggest that targeting the aberrant expression of mTOR regulators p21-activated kinase 4 (PAK4) and nicotinamide phosphoribosyl transferase (NAMPT) sensitizes pNENs to everolimus. In this study, we queried a large real-world data set of pNENs, characterizing the molecular and immune landscapes, as well as the clinical outcomes associated with aberrant PAK4 and NAMPT expression. METHODS Two-hundred and ninety-four pNEN cases were analyzed using next-generation sequencing and whole-exome/whole-transcriptome sequencing. We stratified patients into clusters on the basis of median cutoff. RESULTS High expression of genes activated in response to mTOR activation was found in NAMPT-high and PAK4-high groups. Enrichment of PI3K/AKT/mTOR and glycolysis pathways was observed in these tumors. Higher mutation rates in multiple endocrine neoplasia type 1, alpha thalassemia/mental retardation syndrome X-linked, TSC2, SETD2, and CCNE1 were observed in high NAMPT and PAK4 clusters. Immune analysis revealed enrichment in inflammatory response pathways, IL2/STAT5 signaling, and immune checkpoint genes. Increased neutrophils, natural killer cells, and macrophages were found in PAK4-high/NAMPT-high tumors. Analysis of real-world patient data revealed that high PAK4 ( P = .0428) or NAMPT ( P = .0002) expression individually correlated with lower overall survival in all neuroendocrine neoplasms (NEN) cohorts, while the combined high expression of both was associated with the worst outcomes ( P = .0002). Similar trends were observed in pancreatic NEN cohorts. CONCLUSION Our study demonstrates that PAK4-high/NAMPT-high pNENs are associated with distinct molecular and immune profiles. Further investigation is warranted to determine if dual PAK4 and NAMPT blockade enhances the efficacy of immunotherapeutics.

Year:

2025

PURPOSE Nuclear protein in testis carcinoma (NC) is an underdiagnosed and aggressive squamous/poorly differentiated cancer characterized by rearrangement of the gene NUTM1 on chromosome 15q14. Co-occurring alternations have not been fully characterized. METHODS We analyzed the genomic and immune landscape of 54 cases of NC that underwent DNA- and RNA-based NGS sequencing (Caris). RESULTS While NC is driven by NUTM1 fusion oncoproteins, co-occurring DNA mutations in epigenetic or cell cycle pathways were observed in 26% of cases. There was no significant difference between the fusion partner of NUTM1 and co-occurring gene mutations. RNA sequencing analysis showed increased MYC pathway activity in NC compared with head and neck squamous cell carcinoma (HNSCC) and lung squamous cell carcinoma (LUSC), which is consistent with the known pathophysiology of NC. Characterization of the NC tumor microenvironment using RNA sequencing revealed significantly lower immune cell infiltration compared with HNSCC and LUSC. NC was 10× higher in patients with HNSCC and LUSC younger than 50 years than in those older than 70 years. CONCLUSION To our knowledge, this is the first series of NC profiled broadly at the DNA and RNA level. We observed fewer intratumoral immune cells by RNA sequencing, which may be associated with anecdotal data of lack of immunotherapy benefit in NC. High MYC pathway activity in NC supports ongoing trials targeting MYC suppression. The incidence of NC among patients younger than 50 years with LUSC/HNSCC supports testing for NC in these patients. The prognosis of NCs remains dismal, and future studies should focus on improving the response to immunotherapy and targeting MYC.

Year:

2024

Supplemental Figure 1. Key Biomarkers for KRAS mutation subtypes in adenocarcinoma and squamous cell NSCLC histologies. Frequency of the 10 most common co-occurring mutations including TP53, STK11, ATM, KEAP1, CDKN2A, U2AF1, BRAF, NFE3L2, RAF1 and EGFR are displayed for each KRAS mutation subtype in adenocarcinoma and squamous cell NSCLC cohorts.

Year:

2024

Supplemental Figure 1. Key Biomarkers for KRAS mutation subtypes in adenocarcinoma and squamous cell NSCLC histologies. Frequency of the 10 most common co-occurring mutations including TP53, STK11, ATM, KEAP1, CDKN2A, U2AF1, BRAF, NFE3L2, RAF1 and EGFR are displayed for each KRAS mutation subtype in adenocarcinoma and squamous cell NSCLC cohorts.

Year:

2024

Supplemental Table 2. Immune checkpoint therapy associated markers among KRAS-mutated tumors (A), comparison of these markers between KRAS G12C and all other subtypes (B) and further comparison between G12C, G12A and G13D subtypes (C). * represents p or q values

Year:

2024

Supplemental Table 2. Immune checkpoint therapy associated markers among KRAS-mutated tumors (A), comparison of these markers between KRAS G12C and all other subtypes (B) and further comparison between G12C, G12A and G13D subtypes (C). * represents p or q values

Year:

2024

Supplemental Figure 2 . Differences in co-mutations and immune markers between patients with KRAS mutated (KRAS MT) NSCLC with or without an ATM mutation (ATM MT; A) and between patients with KRAS mutated (KRAS MT) NSCLC with or without a U2AF1 co-mutation (U2AF1 MT; B). (A) Frequency of the 10 most common co-occurring mutations as well as TMB high in patients with tumors harboring KRAS mutations with or without an ATM mutation. (B) Fequency of the 10 most common co-occurring mutation in patients with tumors harboring both KRAS mutations with or without U2AF1 mutations.

Year:

2024

KRAS is the most commonly mutated oncogene in NSCLC and development of direct KRAS inhibitors has renewed interest in this molecular variant. Different KRAS mutations may represent a unique biologic context with different prognostic and therapeutic impact. We sought to characterize genomic landscapes of advanced, KRAS -mutated non–small cell lung cancer (NSCLC) in a large national cohort to help guide future therapeutic development. Molecular profiles of 17,095 NSCLC specimens were obtained using DNA next-generation sequencing of 592 genes (Caris Life Sciences) and classified on the basis of presence and subtype of KRAS mutations. Co-occurring genomic alterations, tumor mutational burden (TMB), and PD-L1 expression [22C3, tumor proportion score (TPS) score] were analyzed by KRAS mutation type. Across the cohort, 4,706 (27.5%) samples harbored a KRAS mutation. The most common subtype was G12C (40%), followed by G12V (19%) and G12D (15%). The prevalence of KRAS mutations was 37.2% among adenocarcinomas and 4.4% in squamous cell carcinomas. Rates of high TMB (≥10 mutations/Mb) and PD-L1 expression varied across KRAS mutation subtypes. KRAS G12C was the most likely to be PD-L1 positive (65.5% TPS ≥ 1%) and PD-L1 high (41.3% TPS ≥ 50%). STK11 was mutated in 8.6% of KRAS wild-type NSCLC but more frequent in KRAS -mutant NSCLC, with the highest rate in G13 (36.2%). TP53 mutations were more frequent in KRAS wild-type NSCLC (73.6%). KRAS mutation subtypes have different co-occurring mutations and a distinct genomic landscape. The clinical relevance of these differences in the context of specific therapeutic interventions warrants investigation.

Year:

2024

Supplemental Figure 2 . Differences in co-mutations and immune markers between patients with KRAS mutated (KRAS MT) NSCLC with or without an ATM mutation (ATM MT; A) and between patients with KRAS mutated (KRAS MT) NSCLC with or without a U2AF1 co-mutation (U2AF1 MT; B). (A) Frequency of the 10 most common co-occurring mutations as well as TMB high in patients with tumors harboring KRAS mutations with or without an ATM mutation. (B) Fequency of the 10 most common co-occurring mutation in patients with tumors harboring both KRAS mutations with or without U2AF1 mutations.

Year:

2024

KRAS is the most commonly mutated oncogene in NSCLC and development of direct KRAS inhibitors has renewed interest in this molecular variant. Different KRAS mutations may represent a unique biologic context with different prognostic and therapeutic impact. We sought to characterize genomic landscapes of advanced, KRAS -mutated non–small cell lung cancer (NSCLC) in a large national cohort to help guide future therapeutic development. Molecular profiles of 17,095 NSCLC specimens were obtained using DNA next-generation sequencing of 592 genes (Caris Life Sciences) and classified on the basis of presence and subtype of KRAS mutations. Co-occurring genomic alterations, tumor mutational burden (TMB), and PD-L1 expression [22C3, tumor proportion score (TPS) score] were analyzed by KRAS mutation type. Across the cohort, 4,706 (27.5%) samples harbored a KRAS mutation. The most common subtype was G12C (40%), followed by G12V (19%) and G12D (15%). The prevalence of KRAS mutations was 37.2% among adenocarcinomas and 4.4% in squamous cell carcinomas. Rates of high TMB (≥10 mutations/Mb) and PD-L1 expression varied across KRAS mutation subtypes. KRAS G12C was the most likely to be PD-L1 positive (65.5% TPS ≥ 1%) and PD-L1 high (41.3% TPS ≥ 50%). STK11 was mutated in 8.6% of KRAS wild-type NSCLC but more frequent in KRAS -mutant NSCLC, with the highest rate in G13 (36.2%). TP53 mutations were more frequent in KRAS wild-type NSCLC (73.6%). KRAS mutation subtypes have different co-occurring mutations and a distinct genomic landscape. The clinical relevance of these differences in the context of specific therapeutic interventions warrants investigation.

Year:

2024

Year:

2023

Collaborators (15)

Jorge Nieva

Professor of Clinical Medicine

University of Southern California

UNITED STATES
View details

Sachin Pai

Assistant Professor

University of South Alabama

UNITED STATES
View details

Hirva Mamdani

Karmanos Cancer Institute

UNITED STATES
View details

Stephen Liu

Associate Professor

Georgetown University School of Medicine

UNITED STATES
View details

Emil Lou

University of Minnesota

UNITED STATES
View details

Bassel El-Rayes

Deputy Director

University of California, San Diego

UNITED STATES
View details

SANJAY GOEL

Rutgers University

UNITED STATES
View details

Ari VanderWalde

Global Head of Clinical Trials

-

UNITED STATES
View details

Bassel Nazha

Emory University School of Medicine

UNITED STATES
View details

Chul Kim

Georgetown University

UNITED STATES
View details

Heloisa Soares

Associate Professor

Huntsman Cancer Institute

UNITED STATES
View details

Trisha M. Wise-Draper

University of Cincinnati

UNITED STATES
View details

Mohd Khushman

Professor

Washington University in St. Louis

UNITED STATES
View details

Boris Pasche

Chair

Karmanos Cancer Institute

UNITED STATES
View details

Luis E. Raez

-

UNITED STATES
View details